Among those with hepatitis B or hepatitis C virus, many were unaware of their infection, supporting the case for more-widespread screening.
Hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV can significantly affect the care of a person with newly diagnosed cancer, yet universal screening is not routine in oncology practices. To inform screening decisions, investigators evaluated the prevalence of these infections among adults with malignancies newly diagnosed between 2013 and 2017 at nine academic and nine community oncology institutions.
A total of 3051 patients (median age, 61; 60% female; 18% black; 18% Hispanic) underwent viral testing. The most common cancers were breast (35%), blood/bone marrow (12%), colorectal (12%), and lung (12%). Previous HBV infection was diagnosed in 6.5% of participants, chronic HBV infection in 0.6%, HCV in 2.4%, and HIV in 1.1%. Forty-two…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)